ALSO NOTED: Novartis gets E.U. nod on Galvus; J&J reps' whistleblower suit tossed out;

> European regulators granted a sigh of relief to Novartis when they OK'd the Swiss drugmaker's type 2 diabetes med Galvus. Report

> Two former reps for Johnson & Johnson saw their whistleblower lawsuit against the company tossed out by a judge this week. Report

> Novartis is proposing to add Ann Fudge, former chairman and CEO of Young & Rubicam Brands, to its board; Fudge also serves on the boards of General Electric and Harvard University. Report

> Mylan got final FDA approval for its generic version of Kytril, Roche's drug for the side effects of cancer treatment. Report

> In an innovative new research pact, scientists from the Medical Research Council in Cambridge and GlaxoSmithKline will collaborate on new work to identify the genetic causes of diseases. Report

> A surge in early-stage drug testing could well set the stage for a spike in lawsuits from patients who feel they've been hurt by the drugs they're volunteering to test, says a new report in The Wall Street Journal. Report

And Finally... Could a drug used to fight a parasite also break into the fortress-like reservoirs HIV builds in the body? Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.